Aleksandra Boldys

Medical University of Silesia

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (4)

Grzegorz Machnik

Medical University of Silesia

POLAND

View details

Mateusz Maligłówka

Medical University of Silesia

POLAND

View details

Rafał Bułdak

Prof.

Opole University

POLAND

View details

Bogusław Okopień

Medical University of Silesia

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aleksandra Boldys

Research Interests

Explore related searches

Contact this professor

Articles (10)

Impact of Short-Term Liraglutide Therapy on Non-Invasive Markers of Liver Fibrosis in Patients with MASLD

Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study

Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers—A Pilot Study

The impact of glucagon and exenatide on oxidative stress levels and antioxidative enzyme expression in in vitro induced steatosis in HepG2 cell culture.

Metabolic dysfunction-associated steatotic liver disease: navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.

Molecular mechanisms behind obesity and their potential exploitation in current and future therapy.

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy

Potential therapeutic strategies in the treatment of metabolic-associated fatty liver disease.

Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner.

Exenatide improves antioxidant capacity and reduces the expression of LDL receptors and PCSK9 in human insulin-secreting 1.1E7 cell line subjected to hyperglycemia and oxidative stress

Collaborators (4)

Grzegorz Machnik

Mateusz Maligłówka

Rafał Bułdak

Bogusław Okopień

Make your next move.